Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Applied DNA Sciences, Inc.

< Previous 1 2 Next >
Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal Regulation
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Submits Validation Package to New York State Department of Health for Approval of Pharmacogenomic (PGx) Assay
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Announces New York State Award Valued at Up To $1.5 Million to Support Establishment of cGMP linearDNA™ Production Capacity on Long Island, New York
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Reports First Quarter Fiscal 2023 Financial Results
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA to Report First Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, February 9, 2023
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Announces Fourth Quarter and Fiscal Year 2022 Financial Results
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA to Report Fiscal 2022 Fourth Quarter and Year End Financial Results on December 14, 2022
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA to Establish North America’s First Enzymatic (Cell Free) Large-Scale cGMP DNA Manufacturing Capacity in Suffolk County, New York
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA’s Biotherapeutics Subsidiary Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Launches Monkeypox Testing Service
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Submits PCR-based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Reports Third Quarter Fiscal 2022 Financial Results
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Biotherapeutics Subsidiary Reports LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Awarded Extension of Health Services Contract with The City University of New York
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA to Host Conference Call and Webcast Discussing Fiscal 2022 Third Quarter Results and Corporate Updates
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Announces Closing of Upsized $12 Million Public Offering
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Announces Pricing of $12 Million Upsized Public Offering, Priced at a Premium to Market Under Nasdaq Rules
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Initiates Analytical Validation of PCR-based Diagnostic Test Specific to Monkeypox Virus
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Biotherapeutics Subsidiary LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Biotherapeutics Subsidiary LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
U.S. Government Guidance Permits DNA Traceability and Isotopic Testing as Evidence under Uyghur Forced Labor Prevention Act
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
Applied DNA Reports Second Quarter Fiscal 2022 Financial Results
From Applied DNA Sciences, Inc.
Via Business Wire
Tickers APDN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.